Skip to main content

Table 1 Baseline characteristics and treatment modalities

From: Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study

Characteristics Total (n = 98)
Demographics:
 Male 70 (71)
 Age at treatment start (yr.) 62 [24–82]
 IMDC score at treatment start (n = 80)
  Favourable risk 19 (24)
  Intermediate risk 40 (50)
  Poor risk 21 (26)
Medical history:
 Hypertension (n = 73) 14 (19)
 Tobacco use (n = 86)
  Active 19 (22)
  Ceased 24 (28)
  None 43 (50)
Tumour characteristics:
 Histology
  Clear cell 85 (87)
  Othera 13 (13)
 Fuhrman grade (n = 79)
  I-II 23 (29)
  III 40 (51)
  IV 16 (20)
 TNM staging (n = 80)
  T1 15 (19)
  T2 21 (26)
  T3–4 44 (55)
  M1 at initial diagnosis 36 (45)
 Pulmonary metastasis (n = 98) 77 (78)
Treatment:
 Prior nephrectomy 86 (88)
 Number of lines of treatment at axitinib start 3 [2–7]
 Treatment duration (mo.) 8 [3–30]
 Causes of axitinib discontinuation (n = 83)
  Progression 57 (68.5)
  Toxicity 13 (15.5)
  Death 9 (11)
  Other 4 (5)
Biology at axitinib start:
 Haemoglobin serum level (g/dL) (n = 98) 12.5 [8.4–16.8]
 Creatinine serum level (μmol/L) (n = 78) 101.5 [39–215]
 Chronic kidney disease (n = 78)
  Grade 1 41 (52)
  Grade 2 36 (46)
  Grade 3 1 (1)
  1. aOther histology was papillary (n = 7), juvenile or Xp11 translocation RCC (n = 4), chromophobe (n = 1), and sarcomatoid (n = 1)